Is Hims & Hers Stock a Buy Right Now in September? | HIMS Stock Analysis
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 16 Sept 2026, 11:45 UTC
- Recorded by Tahlil Plus
- 16 Sept 2026, 15:00 UTC
AI-generated source summary
Hims & Hers Health, Inc. (HIMS) shows a strong upward trend in revenue, projected to exceed $6 billion by 2030. The company has rapidly expanded through acquisitions and new product offerings, increasing its customer base significantly. Despite this growth, profitability metrics such as operating margin and return on invested capital have shown volatility. The operating margin has fluctuated, recently flattening out, while return on invested capital experienced a sharp decline from a peak of nearly 35% in 2025 to -8.44%. The forward P/E ratio has also been volatile, currently trading at 35.25, which is on the lower end of its historical range. The intrinsic value per share is estimated at $27.51, compared to the current market price of $28.81, suggesting it might be slightly overvalued based on this metric. The stock's beta of 2.4 indicates higher volatility compared to the broader healthcare and pharmaceutical sectors, making it more suitable for investors with a higher risk tolerance.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.